Page 59 - 83_02
P. 59
Latency-reversing agents as part of the strategies to cure HIV infection
therapeutic vaccination. AIDS 2015; 30: 553-62. 18. Siliciano JD, Kajdas J, Finzi D, et al. Long-term
follow-up studies confirm the stability of the latent
4. Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, reservoir for HIV-1 in resting CD4+ T cells. Nat Med.
García-Arriaza J, Di Pilato M, Esteban M. The 2003; 9: 727-8.
Evolution of Poxvirus Vaccines. Viruses 2015; 7:
1726-1803. 19. Delagrèverie HM, Delaugerre C, Lewin SR, et al.
Ongoing Clinical Trials of Human Immunodeficiency
5. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. Virus Latency-Reversing and Immunomodulatory
The HIV coreceptors CXCR4 and CCR5 are Agents. Open Forum Infect Dis. 2016; 3: ofw189.
differentially expressed and regulated on human T
lymphocytes. Proc Natl Acad Sci USA. 1997; 94: 20. a) Micheva-Viteva S, Kobayashi Y, Edelstein LC, et
1925-30. al. High-throughput screening uncovers a compound
that activates latent HIV-1 and acts cooperatively with
6. Cary DC, Fujinaga K, Peterlin BM. Molecular a histone deacetylase (HDAC) inhibitor. J Biol Chem.
mechanisms of HIV latency. J Clin Invest. 2016; 126: 2011; 286: 21083-91. b) Xing S, Bhat S, Shroff NS,
448-54. et al. Novel structurally related compounds reactivate
latent HIV-1 in a Bcl-2-transduced primary CD4+ T
7. Harris RS, Hultquist JF, Evans DT. The restriction cell model without inducing global T cell activation. J
factors of human immunodeficiency virus. J Biol Antimicrob Chemother. 2012; 67: 398-403.
Chem. 2012; 287: 40875-83.
21. Matalon S, Rasmussen TA, Dinarello CA. Histone
8. Chun TW, Finzi D, Margolick J, Chadwick K, deacetylase inhibitors for purging HIV-1 from the
Schwartz D, Siliciano RF. In vivo fate of HIV-1- latent reservoir. Mol Med. 2011; 17: 466-72.
infected T cells: quantitative analysis of the transition
to stable latency. Nat Med. 1995;1(12):1284–1290. 22. Ver por ejemplo: Hideshima T, Cottini F, Ohguchi H,
et al. Rational combination treatment with histone
9. Finzi D, Hermankova M, Pierson T, et al. Identification deacetylase inhibitors and immunomodulatory drugs
of a reservoir for HIV-1 in patients on highly active in multiple myeloma. Blood Cancer J. 2015; 5: e312.
antiretroviral therapy. Science 1997; 278: 1295-300.
23. Li H, Wu X. Histone deacetylase inhibitor Trichostatin
10. Siliciano JD, Siliciano RF: A long-term latent reservoir A activates p21WAF1/CIP1 expression through
for HIV-1: discovery and clinical implications. J downregulation of c-Myc and release of the repression
Antimicrob Chemother 2004, 54: 6-9. of c-Myc from the promoter in human cervical cancer
cells. Biochem and Biophys Res Commun. 2004; 324:
11. Pan X, Baldauf H-M, Keppler OT, Fackler OT. 860-7.
Restrictions to HIV-1 replication in resting CD4+ T
lymphocytes. Cell Res. 2013; 23: 876-85. 24. Contreras X, Schweneker M, Chen CS, et al.
Suberoylanilide hydroxamic acid reactivates HIV
12. Xing S, Siliciano RF. Targeting HIV latency: from latently infected cells. J Biol Chem. 2009; 284:
pharmacologic strategies toward eradication. Drug 6782-9.
Discov Today 2013; 18: 541-51.
25. Lehrman G, Hogue IB, Palmer S, et al. Depletion of
13. Prins JM, Jurriaans S, van Praag RM, et al. Immuno- latent HIV-1 infection in vivo: a proof-of-concept
activation with anti-CD3 and recombinant human IL-2 study. Lancet 2005; 366: 549-55.
in HIV-1-infected patients on potent antiretroviral
therapy. AIDS 1999; 13: 2405-10. 26. Ylisastigui L, Coull JJ, Rucker VC, et al. Polyamides
reveal a role for repression in latency within resting T
14. a) Siliciano RF, Greene WC. HIV Latency. Cold cells of HIV-infected donors. J Infect Dis. 2004; 190:
Spring Harb Perspect Med. 2011; 1: a007096. b) 1429-37.
Rasmussen TA, Tolstrup M, Winckelmann A,
Ostergaard L, Søgaard OS. Eliminating the latent HIV 27. Smith SM. Valproic acid and HIV-1 latency: beyond
reservoir by reactivation strategies. Hum Vaccin the sound bite. Retrovirology 2005; 2: 56.
Immunother. 2013; 9: 790-9.
28. Siliciano JD, Lai J, Callender M, et al. Stability of the
15. Yang HC, Xing S, Shan L, et al. Small-molecule Latent Reservoir for HIV-1 in Patients Receiving
screening using a human primary cell model of HIV Valproic Acid. J Infect Diseases 2007; 195: 833-6.
latency identifies compounds that reverse latency
without cellular activation. J Clin Invest. 2009; 119: 29. Schooley RT, Mellors JW. No Cure Yet for HIV-1,
3473-86. But Therapeutic Research Presses On. J Infect
Diseases 2007; 195: 770-2.
16. Bullen CK, Laird GM, Durand ChM, et al. Novel ex
vivo approaches distinguish effective and ineffective 30. Archin NM. Liberty AL, Kashuba AD, et al.
single agents for reversing HIV-1 latency in vivo. Nat Administration of vorinostat disrupts HIV-1 latency in
Med. 2014; 20: 425-9. patients on antiretroviral therapy. Nature 2012; 487:
482-5.
17. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-
1-Specific Cytolytic T Lymphocytes Facilitates 31. Margolis DM. Histone deacetylase inhibitors and HIV
Elimination of Latent Viral Reservoir after Virus latency. Curr Opin HIV AIDS 2011; 6, 25-9.
Reactivation. Immunity 2012; 36: 491-501.
@Real Academia Nacional de Farmacia. Spain 221
